Contact
searchSearch
HMP Global

November 2014 - FRMC

Investigation of Canagliflozin Use in a Real-World Setting
11/14/2014
Eileen Koutnik-Fotopoulos
In a new study, researchers investigated the demographic and clinical factors of patients initiating canagliflozin or DPP-4 therapy in a large commercially insured US population.
In a new study, researchers investigated the demographic and clinical factors of patients initiating canagliflozin or DPP-4 therapy in a large commercially insured US population.
In a new study, researchers...
11/14/2014
First Report Managed Care
Study Examines Cost-Effectiveness of Interferon for MS
11/14/2014
Eileen Koutnik-Fotopoulos
Clinical data from the EVIDENCE study found that the cost-effectiveness of subcutaneous interferon (IFN) ß-1a 44 mcg given 3 times weekly was favorable compared with intramuscular IFN ß-1a 30 mcg given once weekly for relapsing forms of...
Clinical data from the EVIDENCE study found that the cost-effectiveness of subcutaneous interferon (IFN) ß-1a 44 mcg given 3 times weekly was favorable compared with intramuscular IFN ß-1a 30 mcg given once weekly for relapsing forms of...
Clinical data from the EVIDENCE...
11/14/2014
First Report Managed Care
Examining Breakthrough Designation Labeling
11/14/2014
Kerri Fitzgerald
Breakthrough therapy designation was established as part of the FDA Safety and Innovation Act of 2012.
Breakthrough therapy designation was established as part of the FDA Safety and Innovation Act of 2012.
Breakthrough therapy designation...
11/14/2014
First Report Managed Care
Budget Model Analyzes Formulary Costs for Obesity Drugs
11/14/2014
Eileen Koutnik-Fotopoulos
A recent study evaluated formulary cost implications associated with the addition of naltrexone/bupropion for the treatment of obesity in the United States.
A recent study evaluated formulary cost implications associated with the addition of naltrexone/bupropion for the treatment of obesity in the United States.
A recent study evaluated...
11/14/2014
First Report Managed Care
Tbo-Filgrastim Shows Significant Cost Saving for Payers
11/14/2014
Eileen Koutnik-Fotopoulos
A pharmacy budget impact model to estimate, from a payer perspective, the impact of the introduction of tbo-filgrastim as an alternative short-acting granulocyte colony-stimulating factor on a pharmacy budget showed a total annual plan cost...
A pharmacy budget impact model to estimate, from a payer perspective, the impact of the introduction of tbo-filgrastim as an alternative short-acting granulocyte colony-stimulating factor on a pharmacy budget showed a total annual plan cost...
A pharmacy budget impact model...
11/14/2014
First Report Managed Care
More Generics, Biosimilars, and Orphan Drugs on the Horizon
11/14/2014
Jill Sederstorm
As patented products expire, >$13 billion in brand-name specialty medications are expected to face generic competition in the next 5 years, and it is projected that there is a $31.8 billion opportunity in the market for biosimilars through...
As patented products expire, >$13 billion in brand-name specialty medications are expected to face generic competition in the next 5 years, and it is projected that there is a $31.8 billion opportunity in the market for biosimilars through...
As patented products expire,...
11/14/2014
First Report Managed Care
Tools to Help Payers Manage Growing Drug Costs
11/14/2014
Mary Beth Nierengarten
As with other specialty drugs, the high cost of medications to treat hepatitis C presents payers with the challenge of helping their members get the medications they need, while attempting to maintain healthcare costs.
As with other specialty drugs, the high cost of medications to treat hepatitis C presents payers with the challenge of helping their members get the medications they need, while attempting to maintain healthcare costs.
As with other specialty drugs,...
11/14/2014
First Report Managed Care

News

News
Study Examines Costs for Various Psoriasis Treatments
11/14/2014
Eileen Koutnik-Fotopoulos
The economic burden of psoriasis in the United States is significant, as it is estimated to cost $11.25 billion annually in total direct and indirect healthcare costs, according to statistics from the National Psoriasis Foundation.
The economic burden of psoriasis in the United States is significant, as it is estimated to cost $11.25 billion annually in total direct and indirect healthcare costs, according to statistics from the National Psoriasis Foundation.
The economic burden of psoriasis...
11/14/2014
First Report Managed Care

Department

Conference Insider
AMCP Addresses Stance on Federal and State Legislative and Regulatory Moves
11/14/2014
Jill Sederstorm
Legislation on medication therapy management expansion and Medicare drug price negotiations are being discussed on the federal level, while states are considering legislation in the areas of biosimilars, controlled substances, and benefit...
Legislation on medication therapy management expansion and Medicare drug price negotiations are being discussed on the federal level, while states are considering legislation in the areas of biosimilars, controlled substances, and benefit...
Legislation on medication...
11/14/2014
First Report Managed Care
Conference Insider
Paradigm Change: New Guidelines on Managing Cholesterol
11/14/2014
Mary Beth Nierengarten
“This is a large paradigm change for clinicians,” said Joseph Saseen, PharmD, professor, vice chair, department of clinical pharmacy, professor, department of family medicine, University of Colorado Skaggs School of Pharmacy and...
“This is a large paradigm change for clinicians,” said Joseph Saseen, PharmD, professor, vice chair, department of clinical pharmacy, professor, department of family medicine, University of Colorado Skaggs School of Pharmacy and...
“This is a large paradigm change...
11/14/2014
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Authors Call for Novel, Integrated Approaches in RSV Therapeutic Research
04/27/2023
Jolynn Tumolo
In addition to encouraging increased collaboration between bioinformaticians and pharmacologists, the authors recommended the use of new approaches such as nanotechnology, molecular inhibitors, and more.
In addition to encouraging increased collaboration between bioinformaticians and pharmacologists, the authors recommended the use of new approaches such as nanotechnology, molecular inhibitors, and more.
In addition to encouraging...
04/27/2023
Pharmacy Learning Network
News
Examining the Link Between Emergency Department Use and Insurance Coverage
05/26/2023
Julie Gould
“Although Medicaid expansion has provided increased health care coverage for many previously uninsured patients, prior literature suggests that health care utilization and public spending increase with government insurance coverage,” wrote...
“Although Medicaid expansion has provided increased health care coverage for many previously uninsured patients, prior literature suggests that health care utilization and public spending increase with government insurance coverage,” wrote...
“Although Medicaid expansion has...
05/26/2023
First Report Managed Care
Quiz
RSV Vaccine Eligibility
06/21/2023
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now...
06/21/2023
First Report Managed Care
News
Men and Women With MS Perceive Functional Trajectories Differently
07/19/2023
Jolynn Tumolo
“A gap in research about the trajectories of function among men and women aging with functional limitations because of MS hinders ability to plan for future needs,” said researchers. 
“A gap in research about the trajectories of function among men and women aging with functional limitations because of MS hinders ability to plan for future needs,” said researchers. 
“A gap in research about the...
07/19/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Jolynn Tumolo
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care

November 2014 Volume 11 Issue 11

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use